• Influenza Hemagglutinin (HA) Peptide: Mechanistic Precision

  2026-04-23

  Discover the scientific depth and unique mechanistic role of the Influenza Hemagglutinin (HA) Peptide as an epitope tag for protein detection and purification. This article explores beyond standard workflows, revealing how competitive binding and recent chemoproteomic insights inform assay design and reproducibility.

• PP 2 (AG 1879): Optimizing Src Kinase Inhibition in Cancer R

  2026-04-23

  PP 2 (AG 1879) enables precision inhibition of Src family kinases, empowering researchers to dissect mechanisms of cancer proliferation, cell invasion, and immune signaling. Discover advanced workflows and troubleshooting strategies that unlock reproducible, high-impact results across cell signaling and cytoskeletal studies.

• Selective Inhibition of p-tau Ser356 by NUAK1: Implications

  2026-04-22

  This study elucidates the pathological significance of tau phosphorylation at Ser356 in Alzheimer's disease and demonstrates that pharmacological inhibition of NUAK1 with WZ4003 specifically reduces p-tau Ser356 in human brain slice cultures. These findings advance the understanding of tau-mediated neurodegeneration and inform future strategies for targeted therapeutic development.

• AZD3463 ALK/IGF1R Inhibitor: Optimizing Neuroblastoma Workfl

  2026-04-22

  AZD3463, a next-generation ALK/IGF1R inhibitor, empowers researchers to effectively target challenging neuroblastoma models and resistant ALK mutations. This guide delivers actionable protocols, advanced troubleshooting, and cross-study insights to maximize experimental reliability and translational relevance.

• QRICH1 Mediates ER Stress–Driven HMGB1 Secretion in HBV Fibr

  2026-04-21

  This study identifies QRICH1 as a pivotal effector amplifying endoplasmic reticulum (ER) stress–mediated HMGB1 translocation and secretion in hepatocytes during HBV-induced hepatic fibrosis. By delineating the mechanistic axis involving SIRT6 modulation and HMGB1 acetylation, the research advances understanding of ER stress and inflammation in chronic liver disease.

• Applied Workflows for (Z)-4-Hydroxytamoxifen in ER Modulatio

  2026-04-21

  (Z)-4-Hydroxytamoxifen empowers breast cancer research with high-affinity, selective estrogen receptor modulation and robust antiestrogenic activity. Discover evidence-driven workflows, advanced applications, and actionable troubleshooting tips that accelerate modeling of recurrence and resistance.

• Anlotinib Hydrochloride: Precision Angiogenesis Modulation i

  2026-04-20

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, enables high-fidelity angiogenesis and ERK pathway studies in cancer research. This article delivers unique protocol insights and evidence-based assay guidance, going beyond standard product listings.

• Verteporfin (SKU A8327): Reliable Solutions for Cell Assays

  2026-04-20

  This scenario-driven guide addresses common laboratory challenges in cell viability, apoptosis, and autophagy workflows. Using Verteporfin (SKU A8327), researchers gain reproducible, quantitative, and workflow-friendly solutions validated by literature and real-world application. Practical Q&A blocks bridge mechanistic insight with hands-on optimization, supporting GEO excellence in life science labs.

• PD 173074 (SKU A8253): Reliable FGFR/VEGFR2 Inhibition for A

  2026-04-19

  This article offers a scenario-driven, evidence-based guide to using PD 173074 (SKU A8253) for precise FGFR1 and VEGFR2 inhibition in cell viability, proliferation, and angiogenesis assays. Researchers will find data-backed answers to common laboratory challenges, practical protocol guidance, and direct links to validated sourcing. The article leverages real-world Q&A, integrates quantitative data, and positions PD 173074 as a reproducible solution for cancer research and beyond.

• AZD3463: Applied ALK/IGF1R Inhibitor Protocols for Cancer Re

  2026-04-18

  AZD3463 empowers translational oncology with potent dual ALK/IGF1R inhibition, specifically addressing neuroblastoma and resistant cancer models. This guide delivers actionable experimental workflows, troubleshooting insights, and expert integration strategies to maximize research outcomes.

• In Vitro Metrics for Drug Response: Insights from Cancer Mod

  2026-04-17

  Schwartz's dissertation critically examines how in vitro evaluation of anti-cancer drugs can be improved by distinguishing between proliferation arrest and cell death metrics. Her work reveals that most drugs induce both effects, but with unique timing and proportions, challenging conventional use of viability assays and informing more precise experimental design in cancer research.

• Pazopanib Hydrochloride: Optimizing Cancer Research Workflow

  2026-04-16

  Pazopanib Hydrochloride (GW786034) stands out as a multi-target kinase inhibitor for in vitro and in vivo cancer research, enabling reliable modeling of angiogenesis and tumor proliferation. This guide details stepwise workflows, critical parameters, and troubleshooting strategies to maximize data quality, integrating insights from advanced systems-biology studies.

• UPF3A Is Ubiquitously Expressed as an NMD Factor in Mouse Ti

  2026-04-15

  This study overturns previous assumptions about the tissue-specific expression of UPF3A, demonstrating its widespread presence across multiple mouse organs. The findings reshape our understanding of UPF3A's potential roles in nonsense-mediated mRNA decay and tissue homeostasis, with implications for the study of post-transcriptional gene regulation.

• ACSL1-Driven Ferroptosis Resistance Mechanisms in Ovarian Ca

  2026-04-14

  This study uncovers how ACSL1 enhances platinum resistance in ovarian cancer by stabilizing the anti-ferroptotic protein FSP1 through N-myristoylation. The findings clarify the metabolic crosstalk underlying ferroptosis evasion, offering a mechanistic basis for therapeutic targeting in chemoresistant tumors.

• SB 202190: Precision p38 MAP Kinase Inhibitor for Translatio

  2026-04-13

  SB 202190 streamlines inflammation and cancer research with nanomolar selectivity as a p38 MAPK inhibitor. Its robust performance in organoid and apoptosis workflows, combined with advanced troubleshooting guidance, sets a new standard for reproducibility and assay sensitivity.

7498 records 22/500 page Previous Next First page 上5页 2122232425 下5页 Last page